RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases

Company focused on editing the human leukocyte antigen (HLA) to transform autoimmunity Lead program, RG0401, in development for treatment-resistant or refractory rheumatoid arthritis (RA), as a one-time, curative treatment AURORA, Colo., Jan. 9, 2025 /PRNewswire/ — RheumaGen, Inc., a…